Keyuan Pharma held a special meeting on international registration promotion to accelerate the internationalization process
In order to accelerate the pace of the multiple products entering the international market and further expand the development advantages of industrial globalization, Keyuan Pharma (stock code: 301281.SZ) recently held a special meeting on international registration. The senior management, technical R&D team and international registration experts gathered together to discuss and promote the implementation path of international registration of multiple products, and provide variety support for the continuous increase of Keyuan Pharma's export volume.
Under the background of intensified competition in the global pharmaceutical market, Keyuan Pharma, with its strong R&D strength, excellent product quality and stable large-scale production capacity, has deeply cultivated key disease areas such as anti-diabetic, anesthetic, cardiovascular and psychotropic diseases, and has made efforts in both domestic and international markets, continuously achieving new development achievements, and the export share continues to expand.
Many core products of Keyuan Pharma have successively obtained the EU CEP certificate and passed the official pharmaceutical certifications of many countries including the EU EDQM, the US FDA, the Japanese PMDA, and the Korean KFDA, which demonstrates the high quality and international competitiveness of the company's products and provides a strong guarantee to enter the international market.
The meeting emphasized that internationalization is one of the important development strategies of Keyuan Pharma. Accelerating the registration of more API products in the international market is of great significance to enhancing brand influence, broadening sales channels, and increasing export revenue.
The meeting pointed out that Keyuan Pharma will continue to increase investment in product R&D and process optimization, improve product quality and technical level, and ensure that products meet the registration requirements of international regulatory markets such as Europe and the United States. At the same time, Keyuan Pharma will integrate internal and external resources to accelerate the international registration progress of multiple products and support international development strategy to go further and deeper.
The convening of this international registration special meeting marks a solid step forward for Keyuan Pharma on its international development path. As more products are gradually successfully registered in the international market, Keyuan Pharma will further consolidate its position in the international market, the sales territory will usher in a new round of expansion and deepening, and the global layout will reach a new level.
